


## Time to Watch TV (Trump Volatility)

The world is now focusing on the recovery of the economy as more and more countries are gradually lifting the lockdowns. Chart 1 clearly shows that when the lockdown was lifted in China, its PMI, which is an indicator of economic activities also improved. With presidential election in November and less than 6 months for campaign, President Donald Trump has shifted his focus from combating COVID-19 to re-election, re-igniting trade war with China to gain support.



Source: University of Oxford, Bloomberg

President Donald Trump has threatened to impose new trade tariffs against China over its handling of COVID-19 outbreak, and Huawei became his immediate target. However, the banned was insignificant because US components are not widely used in Huawei's phone and merely accounts for 1% of the total costs in Huawei's Mate 30 (Chart 2).

Component	Supplier (Country)	
Processing Chip	HiSilicon(China)	China
	Huizhou Desay Battery	27%
Battery	(China)	21 /0
Modem Chip	HiSilicon(China)	
Antenna Switch	HiSilicon(China)	
Fingerprint Sensor	Goodix (China)	
Rear Camera	Sony (Japan)	Japan
Front Camera	Sony (Japan)	33%
Front end Module	Murata (Japan)	
NAND	Kioxia (Japan)	
Duplexer TDK, Taiyo Yuden		
(Japan)		Korea
OLED Display	Samsung (Korea)	
DRAM	SK Hynix (Korea)	28%
Cover Glass	Corning (US)	
Body Panel	?	US 1%
Touch Panel	?	Inknown: 11%

## Source: Fomalhaut Techno Solutions

It is undoubtedly that post-coronavirus will lead to a more localised economy amid supply chain reshoring, rise in protectionism as well as higher and new forms of taxation. However, this might not happen overnight. Moreover, U.S public health is a matter of national security and U.S. relies heavily on China on some of the medicines, it will be "Kamikaze" for US if China were to ban the export of these medicines. China was accused of unofficially banning of rare earths export to Japan during a diplomatic standoff between the two countries after the 2010 Senkaku boat collision incident. Against this backdrop, we do not expect Trump to have a full-blown conflict with China over the next 3 months (Table 1).

Medicine	U.S. import from China
Antibiotics	97%
Ibuprofen	95%
Hydrocortisone	91%
Acetaminophen	70%
Heparin	50%

Table 1 · U.S. import from China

Source: Vikram Mansharamani, Harvard University

While we are positive on U.S. economic outlook, markets will continue to examine how the pandemic will affect the longer term outlook for the world economy. We believe that the technology sector could be a long-term winner as teleconferencing, teleworking and other technology driven workstyles will become the norm once the pandemic is over.

For those who want to leverage on this opportunity, below is a the list of Top 5 US Funds and Technology Funds based on our scoring that is available through our platform that may be of your interest;

No	US Funds
1	Franklin U.S. Opportunities USD
2	Franklin U.S. Opportunities MYR
3	RHB-GS US Equity
4	Manulife Investment U.S. Equity MYR
5	RHB US Focus Equity
No	Technology Funds
1	United Global Technology MYR
2	TA Global Technology
3	United Global Technology USD
4	Principal Global Technology USD

5 United Global Technology MYR H

Disclaimer: This compilation is prepared by Phillip Mutual Berhad ("PMB") in its capacity as an IUTA approved by the Federation of Investment Managers Malaysia ("FIMM") for specific Funds distributed by PMB. The information contained herein is general information only and not intended for public distribution. It is furnished to the recipient on a confidential basis. It does not take into account your individual objectives, financial situations or needs. You should seek your own professional advisers before investing. No part of this document may be circulated or reproduced without prior permission of PMB and does not constitute an offer, invitation or solicitation to invest in the specific Funds. Any investment product or service offered by PMB is not obligations of, deposits in or guaranteed by PMB. You are advised to read and understand the relevant prospectuses for the Funds, which have been registered with the Securities Commission Malaysia who takes no responsibility for the contents. The respective prospectuses to the Funds are obtainable at any of our offices, website and authorised agents. Any issue of units to which the prospectuses relate will only be made on receipt of the duly completed application form referred to in and accompanying the prospectuses. Investment in unit trust funds is not the same as placing money in a deposit with a financial institution. There are risks involved, and investors should rely on their own evaluation to assess the merits and risks when investing in these funds. There are also fees and charges involved and investors are advised to consider them before investing in theFunds. Investment in shares and bonds may go up as well as down. The prices of units and distribution payable, if any, may also go up as well as down. Past performance of the unit trust funds is not an indication of its future performance. If investors are in any doubt about any feature or nature of the investment, they should consult PMB to obtain further information before investing or seek otherprofessional advice for the suitability of the Funds and to their specific investment needs or financial situations. Information contained herein are based on the law and practise currently in force in Malaysia and are subject to changes in such law without any notice